

# Matthias Engel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/31553/publications.pdf>

Version: 2024-02-01

52  
papers

1,206  
citations

393982

19  
h-index

395343

33  
g-index

54  
all docs

54  
docs citations

54  
times ranked

1467  
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. <i>Nature Chemical Biology</i> , 2009, 5, 758-764.	3.9	134
2	Allosteric activation of the protein kinase PDK1 with low molecular weight compounds. <i>EMBO Journal</i> , 2006, 25, 5469-5480.	3.5	104
3	3,5-Diphenylpent-2-enoic Acids as Allosteric Activators of the Protein Kinase PDK1: Structure-Activity Relationships and Thermodynamic Characterization of Binding as Paradigms for PIF-Binding Pocket-Targeting Compounds—PDB code of <b>2Z2Z</b> with PDK1: 3HRF. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4683-4693.	2.9	72
4	Substrate-Selective Inhibition of Protein Kinase PDK1 by Small Compounds that Bind to the PIF-Pocket Allosteric Docking Site. <i>Chemistry and Biology</i> , 2012, 19, 1152-1163.	6.2	70
5	Allosteric Regulation of Protein Kinase PKC $\eta$ by the N-Terminal C1 Domain and Small Compounds to the PIF-Pocket. <i>Chemistry and Biology</i> , 2011, 18, 1463-1473.	6.2	61
6	Design and Synthesis of a Library of Lead-Like 2,4-Bisheterocyclic Substituted Thiophenes as Selective Dyrk/Clk Inhibitors. <i>PLoS ONE</i> , 2014, 9, e87851.	1.1	43
7	Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5377-5391.	2.9	41
8	Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6101-6107.	2.9	40
9	Hydroxybenzothiophene Ketones Are Efficient Pre-mRNA Splicing Modulators Due to Dual Inhibition of Dyrk1A and Clk1/4. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 963-967.	1.3	40
10	2-(3-Oxo-1,3-diphenylpropyl)malonic Acids as Potent Allosteric Ligands of the PIF Pocket of Phosphoinositide-Dependent Kinase-1: Development and Prodrug Concept. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9817-9830.	2.9	38
11	4-Benzimidazolyl-3-Phenylbutanoic Acids As Novel Pif-Pocket-Targeting Allosteric Inhibitors of Protein Kinase PKC $\eta$ . <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6714-6723.	2.9	35
12	Discovery and Optimization of 1,3,5-Trisubstituted Pyrazolines as Potent and Highly Selective Allosteric Inhibitors of Protein Kinase C- $\eta$ . <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6513-6530.	2.9	33
13	Regulation of the Interaction between Protein Kinase C-related Protein Kinase 2 (PRK2) and Its Upstream Kinase, 3-Phosphoinositide-dependent Protein Kinase 1 (PDK1). <i>Journal of Biological Chemistry</i> , 2009, 284, 30318-30327.	1.6	28
14	First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF- $\kappa$ B Activity As Novel Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2853-2868.	2.9	28
15	First Selective Dual Inhibitors of Tau Phosphorylation and Beta-Amyloid Aggregation, Two Major Pathogenic Mechanisms in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2014, 5, 1198-1202.	1.7	27
16	2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1803-1816.	2.9	25
17	Molecular Mechanism of Regulation of the Atypical Protein Kinase C by N-terminal Domains and an Allosteric Small Compound. <i>Chemistry and Biology</i> , 2014, 21, 754-765.	6.2	24
18	Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism. <i>European Journal of Medicinal Chemistry</i> , 2016, 112, 171-179.	2.6	23

#	ARTICLE	IF	CITATIONS
19	Exploiting the Chromone Scaffold for the Development of Inhibitors of Corticosteroid Biosynthesis. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2468-2477.	2.9	21
20	New biaryl-chalcone derivatives of pregnenolone via Suzuki-Miyaura cross-coupling reaction. Synthesis, CYP17 hydroxylase inhibition activity, QSAR, and molecular docking study. <i>Steroids</i> , 2015, 101, 43-50.	0.8	19
21	Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 1031-1050.	2.6	18
22	Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors. <i>Scientific Reports</i> , 2019, 9, 15893.	1.6	18
23	2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1817-1836.	2.9	17
24	6-Aryl and Heterocycle Quinazoline Derivatives as Potent EGFR Inhibitors with Improved Activity toward Gefitinib-Sensitive and -Resistant Tumor Cell Lines. <i>ChemMedChem</i> , 2013, 8, 1495-1504.	1.6	16
25	Quinazoline and tetrahydropyridothieno[2,3-d]pyrimidine derivatives as irreversible EGFR tyrosine kinase inhibitors: influence of the position 4 substituent. <i>MedChemComm</i> , 2013, 4, 1202.	3.5	16
26	Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 270-285.	2.6	16
27	Design of Novel $\beta$ -Carboline Derivatives with Pendant $\beta$ -Bromothiophenyl and Their Evaluation as Phosphodiesterase-5 Inhibitors. <i>Archiv Der Pharmazie</i> , 2013, 346, 23-33.	2.1	14
28	6-Hydroxybenzothiophene Ketones: Potent Inhibitors of 17 $\beta$ -Hydroxysteroid Dehydrogenase Type-1 (17 $\beta$ -HSD1) Owing to Favorable Molecule Geometry and Conformational Preorganization. <i>ChemMedChem</i> , 2014, 9, 2294-2308.	1.6	14
29	Pharmacological inhibition of protein kinase C (PKC) $\eta$ downregulates the expression of cytokines involved in the pathogenesis of chronic obstructive pulmonary disease (COPD). <i>European Journal of Pharmaceutical Sciences</i> , 2016, 93, 405-409.	1.9	14
30	Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2. <i>European Journal of Medicinal Chemistry</i> , 2016, 112, 209-216.	2.6	14
31	Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors. <i>Bioorganic Chemistry</i> , 2020, 98, 103742.	2.0	14
32	PIF-Pocket as a Target for <i>C. albicans</i> Pkh Selective Inhibitors. <i>ACS Chemical Biology</i> , 2013, 8, 2283-2292.	1.6	13
33	New CYP17 Hydroxylase Inhibitors: Synthesis, Biological Evaluation, QSAR, and Molecular Docking Study of New Pregnenolone Analogs. <i>Archiv Der Pharmazie</i> , 2014, 347, 896-907.	2.1	13
34	From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4462-4477.	2.9	11
35	Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/ $\beta$ -synuclein aggregation inhibitors with neuroprotective effects. <i>European Journal of Medicinal Chemistry</i> , 2022, 227, 113911.	2.6	11
36	Design and synthesis of novel flexible ester-containing analogs of tamoxifen and their evaluation as anticancer agents. <i>Future Medicinal Chemistry</i> , 2016, 8, 249-256.	1.1	10

#	ARTICLE	IF	CITATIONS
37	Design and synthesis of conformationally constraint Dyrk1A inhibitors by creating an intramolecular H-bond involving a benzothiazole core. <i>MedChemComm</i> , 2018, 9, 1045-1053.	3.5	10
38	Synthesis of novel 1,2-diarylpyrazolidin-3-one-based compounds and their evaluation as broad spectrum antibacterial agents. <i>Bioorganic Chemistry</i> , 2020, 99, 103759.	2.0	7
39	Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors. <i>Bioorganic Chemistry</i> , 2020, 104, 104322.	2.0	6
40	Novel 2,4-disubstituted quinazoline analogs as antibacterial agents with improved cytotoxicity profile: Optimization of the 2,4-substituents. <i>Bioorganic Chemistry</i> , 2021, 117, 105422.	2.0	6
41	A new pregnenolone analogues as privileged scaffolds in inhibition of CYP17 hydroxylase enzyme. Synthesis and in silico molecular docking study. <i>Steroids</i> , 2015, 100, 52-59.	0.8	5
42	Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 7343-7356.	1.4	4
43	Synthesis and CYP17 $\alpha$ hydroxylase inhibition activity of new 3 $\beta$ - and 3 $\gamma$ -ester derivatives of pregnenolone and related ether analogues. <i>Medicinal Chemistry Research</i> , 2016, 25, 310-321.	1.1	4
44	5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency. <i>Molecules</i> , 2021, 26, 1001.	1.7	4
45	Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative Diseases. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4302-4318.	1.7	4
46	Development of novel conformationally restricted selective Clk1/4 inhibitors through creating an intramolecular hydrogen bond involving an imide linker. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114411.	2.6	4
47	Screening Dyrk1A inhibitors by MALDI-QqQ mass spectrometry: systematic comparison to established radiometric, luminescence, and LC-UV-MS assays. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 2841-2852.	1.9	3
48	Synthesis and Optimization of New 3,6-Disubstituted indole Derivatives and Their Evaluation as Anticancer Agents Targeting the MDM2/MDM2 Complex. <i>Chemical and Pharmaceutical Bulletin</i> , 2016, 64, 34-41.	0.6	3
49	Design and synthesis of novel 1,3,5-triphenyl pyrazolines as potential anti-inflammatory agents through allosteric inhibition of protein kinase C $\zeta$ (PKC $\zeta$ ). <i>MedChemComm</i> , 2018, 9, 1076-1082.	3.5	2
50	Novel 2,4-disubstituted quinazoline analogs as antibacterial agents with improved cytotoxicity profile: Modification of the benzenoid part. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 59, 128531.	1.0	2
51	Development of (4-Phenylamino)quinazoline Alkylthiourea Derivatives as Novel NF- $\kappa$ B Inhibitors. <i>Pharmaceuticals</i> , 2022, 15, 778.	1.7	2
52	From EGFR kinase inhibitors to anti-inflammatory drugs: Optimization and biological evaluation of (4-(phenylamino)quinazoliny)-phenylthiourea derivatives as novel NF- $\kappa$ B inhibitors. <i>Bioorganic Chemistry</i> , 2022, 127, 105977.	2.0	2